Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024
Inari Medical (NASDAQ: NARI) announced that data from the PEERLESS trial will be presented at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium on October 29th. The trial is a prospective, randomized controlled study comparing outcomes of patients with intermediate-risk pulmonary embolism treated with Inari's FlowTriever system versus catheter-directed thrombolysis.
The primary endpoint is a win-ratio analysis of clinical and hospital resource utilization outcomes. Dr. Wissam Jaber from Emory University School of Medicine will present the findings during the Late-Breaking Clinical Trial Sessions. This study aims to provide critical information on optimal treatment for PE patients and is the first of several RCTs Inari is conducting in the VTE space.
Inari Medical (NASDAQ: NARI) ha annunciato che i dati del trial PEERLESS saranno presentati al Simposio Scientifico Annuale 2024 sulle Terapie Cardiovascolari Transcatetere (TCT) il 29 ottobre. Lo studio è un studio controllato randomizzato prospettico che confronta i risultati dei pazienti con embolia polmonare a rischio intermedio trattati con il FlowTriever system di Inari rispetto alla trombolisi diretta da catetere.
L'endpoint primario è un'analisi del rapporto di vincita degli esiti clinici e dell'utilizzo delle risorse ospedaliere. Il Dr. Wissam Jaber della Emory University School of Medicine presenterà i risultati durante le Sessioni sulle Prove Cliniche di Rottura. Questo studio mira a fornire informazioni critiche sul trattamento ottimale per i pazienti con PE ed è il primo di diversi RCT che Inari sta conducendo nell'area della VTE.
Inari Medical (NASDAQ: NARI) anunció que los datos del ensayo PEERLESS se presentarán en el Simposio Científico Anual 2024 sobre Terapias Cardiovasculares Transcatéter (TCT) el 29 de octubre. El ensayo es un estudio controlado aleatorio prospectivo que compara los resultados de pacientes con embolia pulmonar de riesgo intermedio tratados con el sistema FlowTriever de Inari frente a la trombólisis dirigida por catéter.
El objetivo principal es un análisis de la razón de ganancia de los resultados clínicos y la utilización de recursos hospitalarios. El Dr. Wissam Jaber de la Escuela de Medicina de la Universidad de Emory presentará los hallazgos durante las Sesiones de Ensayos Clínicos de Última Hora. Este estudio tiene como objetivo proporcionar información crítica sobre el tratamiento óptimo para los pacientes con EP y es el primero de varios RCT que Inari está llevando a cabo en el ámbito de la TVE.
이 나리 의료(NASDAQ: NARI)는 2024년 카테터를 통한 심혈관 치료(TCT) 연례 과학 심포지엄에서 PEERLESS 시험의 데이터가 10월 29일 발표될 것이라고 발표했습니다. 이 시험은 나리의 FlowTriever 시스템으로 치료된 중간 위험의 폐색전증 환자와 카테터 유도 혈전 용해 치료를 비교하는 전향적 무작위 대조 연구입니다.
주요 목표는 임상적 및 병원 자원 활용 성과에 대한 승리 비율 분석입니다. 에모리 대학교 의과대학의 드. 위삼 자버가 마지막 발표 임상 시험 세션에서 결과를 발표할 예정입니다. 이 연구는 PE 환자에 대한 최적 치료에 대한 중요한 정보를 제공하는 것을 목표로 하며, VTE 분야에서 Inari가 수행하는 여러 RCT 중 첫 번째입니다.
Inari Medical (NASDAQ: NARI) a annoncé que les données de l'
Le critère principal est une analyse du ratio de gain des résultats cliniques et de l'utilisation des ressources hospitalières. Le Dr. Wissam Jaber de l'École de Médecine de l'Université d'Emory présentera les résultats lors des Sessions de Lancement de Médicaments Clinique. Cette étude vise à fournir des informations critiques sur le traitement optimal des patients PE et est la première de plusieurs ECR qu'Inari mène dans le domaine de la TVE.
Inari Medical (NASDAQ: NARI) gab bekannt, dass Daten aus der PEERLESS-Studie am 29. Oktober beim 2024 Transkatheter-Kardiovaskulären Therapeutika (TCT) Jahreswissenschaftssymposium präsentiert werden. Die Studie ist eine prospektive, randomisierte kontrollierte Studie, die die Ergebnisse von Patienten mit intermediärem Risiko für eine Lungenembolie vergleicht, die mit Inaris FlowTriever-System behandelt wurden, im Vergleich zur kathetergesteuerten Thrombolyse.
Der primäre Endpunkt ist eine Gewinnverhältnis-Analyse der klinischen Ergebnisse und der Nutzung von Krankenhausressourcen. Dr. Wissam Jaber von der Emory University School of Medicine wird die Ergebnisse während der Late-Breaking Clinical Trial Sessions vorstellen. Diese Studie zielt darauf ab, kritische Informationen zur optimalen Behandlung von PE-Patienten bereitzustellen, und ist die erste von mehreren RCTs, die Inari im Bereich der VTE durchführt.
- PEERLESS trial data to be presented at a prestigious scientific symposium (TCT 2024)
- First randomized controlled trial comparing FlowTriever to a historical PE treatment option
- Study may provide critical information for optimal PE patient treatment
- None.
IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that data from the PEERLESS trial will be presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine, during the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The presentation will take place on October 29th.
The PEERLESS trial is a prospective, randomized controlled trial (“RCT”) comparing the outcomes of patients with intermediate-risk pulmonary embolism (“PE”) treated with the FlowTriever system versus catheter-directed thrombolysis. The primary endpoint is a win-ratio analysis of important clinical and hospital resource utilization outcomes. This study will provide critical information to clinicians on the optimal treatment for PE patients.
“PEERLESS is the first RCT directly comparing FlowTriever to a historical treatment option for PE and is the first of several RCTs that Inari is bringing to the VTE space,” said Dr. Thomas Tu, Inari’s Chief Medical Officer. “Patients and physicians deserve high-quality clinical evidence to inform treatment choices and we are thrilled to see this study be presented at TCT.”
About Inari Medical, Inc.
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and four other targeted disease states. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram.
Investor Contact:
Marissa Bych
Gilmartin Group LLC
IR@inarimedical.com
FAQ
What is the PEERLESS trial for Inari Medical (NARI)?
When and where will the PEERLESS trial data for Inari Medical (NARI) be presented?
What is the primary endpoint of Inari Medical's (NARI) PEERLESS trial?
Who will present the PEERLESS trial data for Inari Medical (NARI)?
